The gut microbiome and microbial translocation in multiple sclerosis

Clinical Immunology

Volumn 183, Issue , 2017, Pages 213-224

  Mirza, Ali ^a   Mao Draayer, Yang ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

CNS; Gut brain axis; Intestinal permeability; Microbial translocation; Microbiome; Multiple sclerosis

Indexed keywords

PROBIOTIC AGENT; SHORT CHAIN FATTY ACID;

BACTERIAL TRANSLOCATION; BACTEROIDES; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLOSTRIDIA; CLOSTRIDIUM; DEMYELINATION; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; IMMUNITY; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; MICROGLIA; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; BACTERIUM; CLASSIFICATION; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY;

BACTERIA; BACTERIAL TRANSLOCATION; GASTROINTESTINAL MICROBIOME; HUMANS; MULTIPLE SCLEROSIS;

EID: 85016449053     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2017.03.001     Document Type: Review

References (200)

1. Atlas Multiple Sclerosis Resources in the World 2008. 2008, World health Organization, Multiple Sclerosis International Federation.
2. Multiple Sclerosis. In: Cleveland Clinic [Internet]. [cited 25 Apr 2016]. Available: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/multiple_sclerosis/.
3. Dendrou, C.A., Lars, F., Friese, M.A., Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15 (2015), 545–558.
4. Olsson, T., Barcellos, L.F., Alfredsson, L., Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13 (2017), 25–36.
5. Lucas, R.M., Byrne, S.N., Correale, J., Ilschner, S., Hart, P.H., Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener. Dis Manag. 5 (2015), 413–424.
6. Hogquist, K.A., Jameson, S.C., The self-obsession of T cells: how TCR signaling thresholds affect fate “decisions” and effector function. Nat. Immunol. 15 (2014), 815–823.
7. Benoist, C., Mathis, D., Treg cells, life history, and diversity. Cold Spring Harb. Perspect. Biol., 4, 2012, a007021.
8. Venken, K., Hellings, N., Broekmans, T., Hensen, K., Rummens, J.-L., Stinissen, P., Natural naive CD4 + CD25 + CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J. Immunol. 180 (2008), 6411–6420.
9. Files, D.K., Jausurawong, T., Katrajian, R., Danoff, R., Multiple sclerosis. Prim. Care 42 (2015), 159–175.
10. Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J.P.A., Tzoulaki, I., Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 14 (2015), 263–273.
11. Oksenberg, J.R., Baranzini, S.E., Sawcer, S., Hauser, S.L., The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9 (2008), 516–526.
12. Marchesi, J.R., Ravel, J., The vocabulary of microbiome research: a proposal. Microbiome, 3, 2015, 31.
13. Shreiner, A.B., Kao, J.Y., Young, V.B., The gut microbiome in health and in disease. Curr. Opin. Gastroenterol. 31 (2015), 69–75.
14. Foster, J.A., McVey Neufeld, K.-A., Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 36 (2013), 305–312.
15. Holzer, P., Farzi, A., Neuropeptides and the microbiota-gut-brain axis. Adv. Exp. Med. Biol. 817 (2014), 195–219.
16. Devaraj, S., Hemarajata, P., Versalovic, J., The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin. Chem. 59 (2013), 617–628.
17. Markle, J.G.M., Frank, D.N., Mortin-Toth, S., Robertson, C.E., Feazel, L.M., Rolle-Kampczyk, U., et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339 (2013), 1084–1088.
18. An, D., Dingding, A., Kasper, D.L., Testosterone: more than having the guts to win the tour de France. Immunity 39 (2013), 208–210.
19. Schéle, E., Grahnemo, L., Anesten, F., Hallén, A., Bäckhed, F., Jansson, J.-O., The gut microbiota reduces leptin sensitivity and the expression of the obesity-suppressing neuropeptides proglucagon (Gcg) and brain-derived neurotrophic factor (Bdnf) in the central nervous system. Endocrinology 154 (2013), 3643–3651.
20. Savignac, H.M., Corona, G., Mills, H., Chen, L., Spencer, J.P.E., Tzortzis, G., et al. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochem. Int. 63 (2013), 756–764.
21. Mardinoglu, A., Shoaie, S., Bergentall, M., Ghaffari, P., Zhang, C., Larsson, E., et al. The gut microbiota modulates host amino acid and glutathione metabolism in mice. Mol. Syst. Biol., 11, 2015, 834.
22. Hamer, H.M., Jonkers, D.M.A.E., Bast, A., Vanhoutvin, S.A.L.W., Fischer, M.A.J.G., Kodde, A., et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin. Nutr. 28 (2009), 88–93.
23. Knip, M., Siljander, H., The role of the intestinal microbiota in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 12 (2016), 154–167.
24. Mejía-León, M.E., de la Barca, A.M.C., Diet, microbiota and immune system in type 1 diabetes development and evolution. Nutrients 7 (2015), 9171–9184.
25. Mulak, A., Bonaz, B., Brain-gut-microbiota axis in Parkinson's disease. World J. Gastroenterol. 21 (2015), 10609–10620.
26. Lee, Y.K., Menezes, J.S., Umesaki, Y., Mazmanian, S.K., Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 108:Suppl. 1 (2011), 4615–4622.
27. Ochoa-Repáraz, J., Mielcarz, D.W., Ditrio, L.E., Burroughs, A.R., Foureau, D.M., Haque-Begum, S., et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J. Immunol. 183 (2009), 6041–6050.
28. Berer, K., Mues, M., Koutrolos, M., Rasbi, Z.A., Boziki, M., Johner, C., et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479 (2011), 538–541.
29. Wang, Y., Telesford, K.M., Ochoa-Repáraz, J., Haque-Begum, S., Christy, M., Kasper, E.J., et al. An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling. Nat. Commun., 5, 2014, 4432.
30. Lavasani, S., Shahram, L., Balik, D., Mehrnaz, N., Frida, F., Sophia, B., et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One, 5, 2010, e9009.
31. Molloy, M.J., Nicolas, B., Yasmine, B., Intestinal microbiota: shaping local and systemic immune responses. Semin. Immunol. 24 (2012), 58–66.
32. Lathrop, S.K., Bloom, S.M., Rao, S.M., Nutsch, K., Lio, C.-W., Santacruz, N., et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 478 (2011), 250–254.
33. Belkaid, Y., Naik, S., Compartmentalized and systemic control of tissue immunity by commensals. Nat. Immunol. 14 (2013), 646–653.
34. Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Toth, M., et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci. Transl. Med., 6, 2014, 263ra158.
35. Erny, D., Hrabě de Angelis, A.L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18 (2015), 965–977.
36. Rothhammer, V., Mascanfroni, I.D., Bunse, L., Takenaka, M.C., Kenison, J.E., Mayo, L., et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med., 2016, 10.1038/nm.4106.
37. Hoban, A.E., Stilling, R.M., Ryan, F.J., Shanahan, F., Dinan, T.G., Claesson, M.J., et al. Regulation of prefrontal cortex myelination by the microbiota. Transl. Psychiatry, 6, 2016, e774.
38. Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., de Roos, P., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504 (2013), 451–455.
39. Haghikia, A., Jörg, S., Duscha, A., Berg, J., Manzel, A., Waschbisch, A., et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 43 (2015), 817–829.
40. Borody, T., Leis, S., Campbell, J., Torres, M., Nowak, A., centre for Digestive Diseases, Five Fock, NSW, Australia, Fecal microbiota transplantation (FMT) in multiple sclerosis (MS) [abstract]. Am. J. Gastroenterol., 106, 2011.
41. Miyake, S., Kim, S., Suda, W., Oshima, K., Nakamura, M., Matsuoka, T., et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PLoS One, 10, 2015, e0137429.
42. Matsen, F.A., Kodner, R.B., Armbrust, E.V., pplacer: linear time maximum-likelihood and Bayesian phylogenetic placement of sequences onto a fixed reference tree. BMC Bioinf., 11, 2010, 538.
43. Jangi, S., Sushrut, J., Roopali, G., Cox, L.M., Ning, L., von Glehn, F., et al. Alterations of the human gut microbiome in multiple sclerosis. Nat. Commun., 7, 2016, 12015.
44. Chen, J., Chia, N., Kalari, K.R., Yao, J.Z., Novotna, M., Soldan, M.M.P., et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci. Rep., 6, 2016, 28484.
45. Langille, M.G.I., Zaneveld, J., Caporaso, J.G., McDonald, D., Knights, D., Reyes, J.A., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 31 (2013), 814–821.
46. Tremlett, H., Fadrosh, D.W., Faruqi, A.A., Zhu, F., Hart, J., Roalstad, S., et al. Gut microbiota in early pediatric multiple sclerosis: a case − control study. Eur. J. Neurol. 23 (2016), 1308–1321.
47. Tremlett, H., Helen, T., Fadrosh, D.W., Faruqi, A.A., Janace, H., Shelly, R., et al. Gut microbiota composition and relapse risk in pediatric MS: a pilot study. J. Neurol. Sci. 363 (2016), 153–157.
48. Cantarel, B.L., Waubant, E., Chehoud, C., Kuczynski, J., DeSantis, T.Z., Warrington, J., et al. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J. Investig. Med. 63 (2015), 729–734.
49. Hold, G.L., Pryde, S.E., Russell, V.J., Furrie, E., Flint, H.J., Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol. Ecol. 39 (2002), 33–39.
50. Manson, J.M., Rauch, M., Gilmore, M.S., The commensal microbiology of the gastrointestinal tract. Adv. Exp. Med. Biol. 635 (2008), 15–28.
51. Lopetuso, L.R., Scaldaferri, F., Petito, V., Gasbarrini, A., Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog., 5, 2013, 23.
52. Van den Abbeele, P., Clara, B., Margot, G., Michiel, K., De Vos, W.M., Olivier, T., et al. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J. 7 (2012), 949–961.
53. Duncan, S.H., Barcenilla, A., Stewart, C.S., Pryde, S.E., Flint, H.J., Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl. Environ. Microbiol. 68 (2002), 5186–5190.
54. Duncan, S.H., Louis, P., Flint, H.J., Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl. Environ. Microbiol. 70 (2004), 5810–5817.
55. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L.G., Gratadoux, J.-J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 16731–16736.
56. Suau, A., Rochet, V., Sghir, A., Gramet, G., Brewaeys, S., Sutren, M., et al. Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst. Appl. Microbiol. 24 (2001), 139–145.
57. Kabeerdoss, J., Jayakanthan, K., Vijayalakshmi, S., Srinivasan, P., Ramakrishna, B.S., Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case–control study in India. BMC Gastroenterol., 13, 2013, 20.
58. Takahashi, K., Nishida, A., Fujimoto, T., Fujii, M., Shioya, M., Imaeda, H., et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease. Digestion 93 (2016), 59–65.
59. Lopez-Siles, M., Martinez-Medina, M., Surís-Valls, R., Aldeguer, X., Sabat-Mir, M., Duncan, S.H., et al. Changes in the abundance of Faecalibacterium prausnitzii phylogroups I and II in the intestinal mucosa of inflammatory bowel disease and patients with colorectal cancer. Inflamm. Bowel Dis. 22 (2016), 28–41.
60. Hedin, C.R., McCarthy, N.E., Louis, P., Farquharson, F.M., McCartney, S., Taylor, K., et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 63 (2014), 1578–1586.
61. Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63 (2014), 1275–1283.
62. McLaughlin, S.D., Walker, A.W., Churcher, C., Clark, S.K., Tekkis, P.P., Johnson, M.W., et al. The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Ann. Surg. 252 (2010), 90–98.
63. Rajilić-Stojanović, M., Mirjana, R., Elena, B., Heilig, H.G.H.J., Kajsa, K., Kekkonen, R.A., et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141 (2011), 1792–1801.
64. Swidsinski, A., Loening-Baucke, V., Verstraelen, H., Osowska, S., Doerffel, Y., Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 135 (2008), 568–579.
65. Sobhani, I., Iradj, S., Julien, T., Françoise, R.-T., Roperch, J.P., Sophie, L., et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One, 6, 2011, e16393.
66. Balamurugan, R., Rajendiran, E., George, S., Samuel, G.V., Ramakrishna, B.S., Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J. Gastroenterol. Hepatol. 23 (2008), 1298–1303.
67. Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490 (2012), 55–60.
68. Bruzzese, E., Callegari, M.L., Raia, V., Viscovo, S., Scotto, R., Ferrari, S., et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One, 9, 2014, e87796.
69. de Goffau, M.C., Luopajärvi, K., Knip, M., Ilonen, J., Ruohtula, T., Härkönen, T., et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes 62 (2013), 1238–1244.
70. Stoll, M.L., Kumar, R., Morrow, C.D., Lefkowitz, E.J., Cui, X., Genin, A., et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res. Ther., 16, 2014, 486.
71. Candela, M., Rampelli, S., Turroni, S., Severgnini, M., Consolandi, C., De Bellis, G., et al. Unbalance of intestinal microbiota in atopic children. BMC Microbiol., 12, 2012, 95.
72. De Palma, G., Nadal, I., Medina, M., Donat, E., Ribes-Koninckx, C., Calabuig, M., et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol., 10, 2010, 63.
73. Rossi, O., Oriana, R., van Berkel, L.A., Florian, C., Tanweer Khan, M., Nico, T., et al. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci. Rep., 6, 2016, 18507.
74. Miquel, S., Sylvie, M., Marion, L., Rebeca, M., Florian, C., Marion, L., et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio 6 (2015), e00300–e00315.
75. Martín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J.-J., Sokol, H., et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm. Bowel Dis. 20 (2014), 417–430.
76. Zhang, M., Qiu, X., Zhang, H., Yang, X., Hong, N., Yang, Y., et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One, 9, 2014, e109146.
77. Miquel, S., Martín, R., Lashermes, A., Gillet, M., Meleine, M., Gelot, A., et al. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci. Rep., 6, 2016, 19399.
78. Martín, R., Rebeca, M., Sylvie, M., Florian, C., Natividad, J.M., Jennifer, J., et al. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol., 15, 2015, 10.1186/s12866-015-0400-1.
79. Carlsson, A.H., Yakymenko, O., Olivier, I., Håkansson, F., Postma, E., Keita, A.V., et al. Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis. Scand. J. Gastroenterol. 48 (2013), 1136–1144.
80. Quévrain, E., Maubert, M.A., Michon, C., Chain, F., Marquant, R., Tailhades, J., et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65 (2016), 415–425.
81. Lührs, H., Gerke, T., Schauber, J., Dusel, G., Melcher, R., Scheppach, W., et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int. J. Color. Dis. 16 (2001), 195–201.
82. Segain, J.P., Raingeard de la Blétière, D., Bourreille, A., Leray, V., Gervois, N., Rosales, C., et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47 (2000), 397–403.
83. Wexler, H.M., Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20 (2007), 593–621.
84. Wang, Y., Yan, W., Sakhina, B.-H., Telesford, K.M., Javier, O.-R., Marc, C., et al. A commensal bacterial product elicits and modulates migratory capacity of CD39 CD4 T regulatory subsets in the suppression of neuroinflammation. Gut Microbes 5 (2014), 552–561.
85. Paquin-Proulx, D., Ching, C., Vujkovic-Cvijin, I., Fadrosh, D., Loh, L., Huang, Y., et al. Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection. Mucosal Immunol., 2016, 10.1038/mi.2016.34.
86. Vatanen, T., Kostic, A.D., d'Hennezel, E., Siljander, H., Franzosa, E.A., Yassour, M., et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 165 (2016), 842–853.
87. Pudlo, N.A., Urs, K., Kumar, S.S., German, J.B., Mills, D.A., Martens, E.C., Symbiotic human gut bacteria with variable metabolic priorities for host mucosal glycans. MBio, 6, 2015 (e01282–15).
88. Derrien, M., Muriel, D., Clara, B., de Vos, W.M., Akkermansia muciniphila and its role in regulating host functions. Microb. Pathog., 2016, 10.1016/j.micpath.2016.02.005.
89. Venugopal, A.A., Szpunar, S., Johnson, L.B., Risk and prognostic factors among patients with bacteremia due to Eggerthella lenta. Anaerobe 18 (2012), 475–478.
90. Gardiner, B.J., Tai, A.Y., Kotsanas, D., Francis, M.J., Roberts, S.A., Ballard, S.A., et al. Clinical and microbiological characteristics of Eggerthella lenta bacteremia. J. Clin. Microbiol. 53 (2015), 626–635.
91. Minter, M.R., Can, Z., Vanessa, L., Ringus, D.L., Xiaoqiong, Z., Paul, O.-C., et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci. Rep., 6, 2016, 30028.
92. Vital, M., Howe, A.C., Tiedje, J.M., Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio, 5, 2014, e00889.
93. Kant, R., Ravi, K., Pia, R., Reetta, S., Pietilä, T.E., Airi, P., Genome sequence of the butyrate — producing anaerobic bacterium Anaerostipes hadrus PEL 85. Genome Announc., 3, 2015 (e00224–15).
94. Canani, R.B., Costanzo, M.D., Leone, L., Pedata, M., Meli, R., Calignano, A., Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J. Gastroenterol. 17 (2011), 1519–1528.
95. Keku, T.O., Santosh, D., April, D., Biljana, J., Xuesong, H., The gastrointestinal microbiota and colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 308 (2014), G351–G363.
96. Roy, C.C., Kien, C.L., Bouthillier, L., Levy, E., Short-chain fatty acids: ready for prime time?. Nutr. Clin. Pract. 21 (2006), 351–366.
97. Cook, S.I., Sellin, J.H., Review article: short chain fatty acids in health and disease. Aliment. Pharmacol. Ther. 12 (1998), 499–507.
98. Ganapathy, V., Thangaraju, M., Prasad, P.D., Martin, P.M., Singh, N., Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Curr. Opin. Pharmacol. 13 (2013), 869–874.
99. Kim, C.H., Jeongho, P., Myunghoo, K., Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. Immune Netw., 14, 2014, 277.
100. Singh, N., Thangaraju, M., Prasad, P.D., Martin, P.M., Lambert, N.A., Boettger, T., et al. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J. Biol. Chem. 285 (2010), 27601–27608.
101. Gurav, A., Ashish, G., Sathish, S., Bhutia, Y.D., Thomas, B., Nagendra, S., et al. Slc5a8, a Na -coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon that protects against colitis and colon cancer under low-fibre dietary conditions. Biochem. J. 469 (2015), 267–278.
102. Waldecker, M., Kautenburger, T., Daumann, H., Busch, C., Schrenk, D., Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J. Nutr. Biochem. 19 (2008), 587–593.
103. Farrokhi, V., Vahid, F., Reza, N., Nichols, F.C., Xudong, Y., Emily, A., et al. Bacterial lipodipeptide, lipid 654, is a microbiome-associated biomarker for multiple sclerosis. Clin. Transl. Immunol., 2, 2013, e8.
104. Clark, R.B., Cervantes, J.L., Maciejewski, M.W., Farrokhi, V., Nemati, R., Yao, X., et al. Serine lipids of Porphyromonas gingivalis are human and mouse toll-like receptor 2 ligands. Infect. Immun. 81 (2013), 3479–3489.
105. Anstadt, E.J., Fujiwara, M., Wasko, N., Nichols, F., Clark, R.B., TLR tolerance as a treatment for central nervous system autoimmunity. J. Immunol., 2016, 10.4049/jimmunol.1600876.
106. Shen, Y., Giardino Torchia, M.L., Lawson, G.W., Karp, C.L., Ashwell, J.D., Mazmanian, S.K., Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 12 (2012), 509–520.
107. Telesford, K.M., Yan, W., Ochoa-Reparaz, J., Pant, A., Kircher, C., Christy, M.A., et al. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function. Gut Microbes 6 (2015), 234–242.
108. Mehta, N.N., McGillicuddy, F.C., Anderson, P.D., Hinkle, C.C., Shah, R., Pruscino, L., et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 59 (2010), 172–181.
109. de Punder, K., Pruimboom, L., Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front. Immunol., 6, 2015, 223.
110. Teixeira, B., Bittencourt, V.C.B., Ferreira, T.B., Kasahara, T.M., Barros, P.O., Alvarenga, R., et al. Low sensitivity to glucocorticoid inhibition of in vitro Th17-related cytokine production in multiple sclerosis patients is related to elevated plasma lipopolysaccharide levels. Clin. Immunol. 148 (2013), 209–218.
111. Fasano, A., Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol. Rev. 91 (2011), 151–175.
112. Buscarinu, M.C., Cerasoli, B., Annibali, V., Policano, C., Lionetto, L., Capi, M., et al. Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: a pilot study. Mult. Scler., 2016, 10.1177/1352458516652498.
113. Aravindhan, V., Mohan, V., Arunkumar, N., Sandhya, S., Babu, S., Chronic endotoxemia in subjects with type-1 diabetes is seen much before the onset of microvascular complications. PLoS One, 10, 2015, e0137618.
114. Zhang, R., Miller, R.G., Gascon, R., Champion, S., Katz, J., Lancero, M., et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 206 (2009), 121–124.
115. Emanuele, E., Orsi, P., Boso, M., Broglia, D., Brondino, N., Barale, F., et al. Low-grade endotoxemia in patients with severe autism. Neurosci. Lett. 471 (2010), 162–165.
116. Sandler, N.G., Douek, D.C., Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat. Rev. Microbiol. 10 (2012), 655–666.
117. Jiang, W., Lederman, M.M., Hunt, P., Sieg, S.F., Haley, K., Rodriguez, B., et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199 (2009), 1177–1185.
118. Farhadi, A., Banan, A., Fields, J., Keshavarzian, A., Intestinal barrier: an interface between health and disease. J. Gastroenterol. Hepatol. 18 (2003), 479–497.
119. Balda, M.S., Matter, K., Tight junctions at a glance. J. Cell Sci. 121 (2008), 3677–3682.
120. Ivanov, A.I., Parkos, C.A., Nusrat, A., Cytoskeletal regulation of epithelial barrier function during inflammation. Am. J. Pathol. 177 (2010), 512–524.
121. Kelly, C.J., Colgan, S.P., Frank, D.N., Of microbes and meals: the health consequences of dietary endotoxemia. Nutr. Clin. Pract. 27 (2012), 215–225.
122. Cao, X., Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat. Rev. Immunol. 16 (2016), 35–50.
123. Kigerl, K.A., de Rivero Vaccari, J.P., Dietrich, W.D., Popovich, P.G., Keane, R.W., Pattern recognition receptors and central nervous system repair. Exp. Neurol. 258 (2014), 5–16.
124. Nagyőszi, P., Péter, N., Ádám, N.-T., Csilla, F., Imola, W., Mihály, K., et al. Regulation of NOD-like receptors and inflammasome activation in cerebral endothelial cells. J. Neurochem. 135 (2015), 551–564.
125. Suresh, R., Mosser, D.M., Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv. Physiol. Educ. 37 (2013), 284–291.
126. Clarke, T.B., Davis, K.M., Lysenko, E.S., Zhou, A.Y., Yu, Y., Weiser, J.N., Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16 (2010), 228–231.
127. Ichinohe, T., Pang, I.K., Kumamoto, Y., Peaper, D.R., Ho, J.H., Murray, T.S., et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 5354–5359.
128. Abt, M.C., Osborne, L.C., Monticelli, L.A., Doering, T.A., Alenghat, T., Sonnenberg, G.F., et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37 (2012), 158–170.
129. Fasano, A., Alessio, F., Zonulin, regulation of tight junctions, and autoimmune diseases. Ann. N. Y. Acad. Sci. 1258 (2012), 25–33.
130. Mills, K.H.G., TLR-dependent T cell activation in autoimmunity. Nat. Rev. Immunol. 11 (2011), 807–822.
131. Yang, Y., Yiping, Y., Ching-Tai, H., Xiaopei, H., Pardoll, D.M., Persistent toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance. Nat. Immunol. 5 (2004), 508–515.
132. Oberg, H.-H., Ly, T.T.H., Ussat, S., Meyer, T., Kabelitz, D., Wesch, D., Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J. Immunol. 184 (2010), 4733–4740.
133. Wing, K., Sakaguchi, S., Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11 (2010), 7–13.
134. Round, J.L., O'Connell, R.M., Mazmanian, S.K., Coordination of tolerogenic immune responses by the commensal microbiota. J. Autoimmun. 34 (2010), J220–J225.
135. Nyirenda, M.H., Sanvito, L., Darlington, P.J., O'Brien, K., Zhang, G.-X., Constantinescu, C.S., et al. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J. Immunol. 187 (2011), 2278–2290.
136. Schmaler, M., Jann, N.J., Ferracin, F., Landmann, R., T and B cells are not required for clearing Staphylococcus aureus in systemic infection despite a strong TLR2-MyD88-dependent T cell activation. J. Immunol. 186 (2010), 443–452.
137. Shi, C., Jia, T., Mendez-Ferrer, S., Hohl, T.M., Serbina, N.V., Lipuma, L., et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 34 (2011), 590–601.
138. Chuluundorj, D., Harding, S.A., Abernethy, D., La Flamme, A.C., Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis. Immunol. Cell Biol. 92 (2014), 509–517.
139. Neves, A.L., Coelho, J., Couto, L., Leite-Moreira, A., Roncon-Albuquerque, R. Jr., Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J. Mol. Endocrinol. 51 (2013), R51–R64.
140. Akira, S., Toll-like receptors and innate immunity. Adv. Immunol. 78 (2001), 1–56.
141. Bohannon, J.K., Hernandez, A., Enkhbaatar, P., Adams, W.L., Sherwood, E.R., The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants. Shock 40 (2013), 451–462.
142. Lu, Y.-C., Kim, I., Lye, E., Shen, F., Suzuki, N., et al. Differential role for c-Rel and C/EBP / in TLR-mediated induction of proinflammatory cytokines. J. Immunol. 182 (2009), 7212–7221.
143. Cavaillon, J.-M., Adib-Conquy, M., Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care, 10, 2006, 233.
144. Zhou, L., Liang, Z., Ivanov, I.I., Rosanne, S., Roy, M., Kevin, S., et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8 (2007), 967–974.
145. Acosta-Rodriguez, E.V., Giorgio, N., Antonio, L., Federica, S., Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells. Nat. Immunol. 8 (2007), 942–949.
146. Okuda, Y., IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10 (1998), 703–708.
147. Hoogland, I.C.M., Houbolt, C., van Westerloo, D.J., van Gool, W.A., van de Beek, D., Systemic inflammation and microglial activation: systematic review of animal experiments. J. Neuroinflammation, 12, 2015, 114.
148. Marinelli, C., Di Liddo, R., Facci, L., Bertalot, T., Conconi, M.T., Zusso, M., et al. Ligand engagement of toll-like receptors regulates their expression in cortical microglia and astrocytes. J. Neuroinflammation, 12, 2015, 244.
149. Shi, J., Liu, X., Xu, C., Ge, J., Ren, J., Wang, J., et al. Up-regulation of PSMB4 is associated with neuronal apoptosis after neuroinflammation induced by lipopolysaccharide. J. Mol. Histol. 46 (2015), 457–466.
150. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
151. Peng, L., Li, Z.-R., Green, R.S., Holzman, I.R., Lin, J., Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J. Nutr. 139 (2009), 1619–1625.
152. Jung, T.-H., Park, J.H., Jeon, W.-M., Han, K.-S., Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr. Res. Pract. 9 (2015), 343–349.
153. Xu, M.-Q., Cao, H.-L., Wang, W.-Q., Wang, S., Cao, X.-C., Yan, F., et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J. Gastroenterol. 21 (2015), 102–111.
154. Kelly, C.R., Stacy, K., Purna, K., Loren, L., David, R., Ashish, A., et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149 (2015), 223–237.
155. Petrof, E.O., Gloor, G.B., Vanner, S.J., Weese, S.J., David, C., Daigneault, M.C., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: “RePOOPulating” the gut. Microbiome, 1, 2013, 3.
156. Adamu, B.O., Lawley, T.D., Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Curr. Opin. Microbiol. 16 (2013), 596–601.
157. Sanders, M.E., Probiotics: definition, sources, selection, and uses. Clin. Infect. Dis. 46:Suppl. 2 (2008), S58–S61 (discussion S144–51).
158. Lavasani, S., Shahram, L., Balik, D., Mehrnaz, N., Frida, F., Sophia, B., et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One, 5, 2010, e9009.
159. Okuno, T., Tatsusada, O., Yuji, N., Makoto, K., Kazushiro, T., Toru, K., et al. The role of gut microbiota and diet in experimental autoimmune encephalitis and multiple sclerosis. Clin. Exp. Neuroimmunol. 6 (2015), 30–37.
160. Hutkins, R.W., Krumbeck, J.A., Bindels, L.B., Cani, P.D., Fahey, G. Jr., Goh, Y.J., et al. Prebiotics: why definitions matter. Curr. Opin. Biotechnol. 37 (2016), 1–7.
161. A Report of the Panel on Macronutrients, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). 2005, National Academies Press.
162. Konner, M., Eaton, S.B., Paleolithic nutrition: twenty-five years later. Nutr. Clin. Pract. 25 (2010), 594–602.
163. Schnorr, S.L., Candela, M., Rampelli, S., Centanni, M., Consolandi, C., Basaglia, G., et al. Gut microbiome of the Hadza hunter-gatherers. Nat. Commun., 5, 2014, 3654.
164. Sharon, G., Garg, N., Debelius, J., Knight, R., Dorrestein, P.C., Mazmanian, S.K., Specialized metabolites from the microbiome in health and disease. Cell Metab. 20 (2014), 719–730.
165. Cardona, F., Andrés-Lacueva, C., Tulipani, S., Tinahones, F.J., Queipo-Ortuño, M.I., Benefits of polyphenols on gut microbiota and implications in human health. J. Nutr. Biochem. 24 (2013), 1415–1422.
166. Kouakou, K., Schepetkin, I.A., Jun, S., Kirpotina, L.N., Yapi, A., Khramova, D.S., et al. Immunomodulatory activity of polysaccharides isolated from Clerodendrum splendens: beneficial effects in experimental autoimmune encephalomyelitis. BMC Complement. Altern. Med., 13, 2013, 149.
167. Larrosa, M., Luceri, C., Vivoli, E., Pagliuca, C., Lodovici, M., Moneti, G., et al. Polyphenol metabolites from colonic microbiota exert anti-inflammatory activity on different inflammation models. Mol. Nutr. Food Res. 53 (2009), 1044–1054.
168. Akiyama, H., Sato, Y., Watanabe, T., Nagaoka, M.H., Yoshioka, Y., Shoji, T., et al. Dietary unripe apple polyphenol inhibits the development of food allergies in murine models. FEBS Lett. 579 (2005), 4485–4491.
169. Varilek, G.W., Yang, F., Lee, E.Y., de Villiers, W.J., Zhong, J., Oz, H.S., et al. Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J. Nutr. 131 (2001), 2034–2039.
170. Haqqi, T.M., Anthony, D.D., Gupta, S., Ahmad, N., Lee, M.S., Kumar, G.K., et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 4524–4529.
171. Miyake, M., Sasaki, K., Ide, K., Matsukura, Y., Shijima, K., Fujiwara, D., Highly oligomeric procyanidins ameliorate experimental autoimmune encephalomyelitis via suppression of Th1 immunity. J. Immunol. 176 (2006), 5797–5804.
172. Allen, J.E., Maizels, R.M., Diversity and dialogue in immunity to helminths. Nat. Rev. Immunol. 11 (2011), 375–388.
173. Helmby, H., Helena, H., Human helminth therapy to treat inflammatory disorders — where do we stand?. BMC Immunol., 16, 2015, 12.
174. La Flamme, A.C., Ruddenklau, K., Bäckström, B.T., Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect. Immun. 71 (2003), 4996–5004.
175. Walsh, K.P., Brady, M.T., Finlay, C.M., Boon, L., Mills, K.H.G., Infection with a helminth parasite attenuates autoimmunity through TGF- mediated suppression of Th17 and Th1 responses. J. Immunol. 183 (2009), 1577–1586.
176. Correale, J., Jorge, C., Mauricio, F., Association between parasite infection and immune responses in multiple sclerosis. Ann. Neurol. 61 (2007), 97–108.
177. Fleming, J.O., Isaak, A., Lee, J.E., Luzzio, C.C., Carrithers, M.D., Cook, T.D., et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult. Scler. 17 (2011), 743–754.
178. Voldsgaard, A., Bager, P., Garde, E., Åkeson, P., Leffers, A.M., Madsen, C.G., et al. Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Mult. Scler. 21 (2015), 1723–1729.
179. Manzel, A., Arndt, M., Muller, D.N., Hafler, D.A., Erdman, S.E., Linker, R.A., et al. Role of “Western Diet” in inflammatory autoimmune diseases. Curr. Allergy Asthma Rep., 14, 2013, 10.1007/s11882-013-0404-6.
180. Sonnenburg, E.D., Smits, S.A., Tikhonov, M., Higginbottom, S.K., Wingreen, N.S., Sonnenburg, J.L., Diet-induced extinctions in the gut microbiota compound over generations. Nature 529 (2016), 212–215.
181. Lerner, A., Matthias, T., Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun. Rev. 14 (2015), 479–489.
182. Berg, A.M., Kelly, C.P., Farraye, F.A., Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm. Bowel Dis. 19 (2013), 194–204.
183. Jin, Y., Zeng, Z., Wu, Y., Zhang, S., Fu, Z., Oral exposure of mice to carbendazim induces hepatic lipid metabolism disorder and gut microbiota dysbiosis. Toxicol. Sci. 147 (2015), 116–126.
184. Chassaing, B., Koren, O., Goodrich, J.K., Poole, A.C., Srinivasan, S., Ley, R.E., et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519 (2015), 92–96.
185. Khalili, H., Risk of inflammatory bowel disease with oral contraceptives and menopausal hormone therapy: current evidence and future directions. Drug Saf. 39 (2016), 193–197.
186. Fujimori, S., What are the effects of proton pump inhibitors on the small intestine?. World J. Gastroenterol. 21 (2015), 6817–6819.
187. Syer, S.D., Blackler, R.W., Martin, R., de Palma, G., Rossi, L., Verdu, E., et al. NSAID enteropathy and bacteria: a complicated relationship. J. Gastroenterol. 50 (2015), 387–393.
188. Dominguez-Bello, M.G., De Jesus-Laboy, K.M., Shen, N., Cox, L.M., Amir, A., Gonzalez, A., et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat. Med. 22 (2016), 250–253.
189. O'Sullivan, A., Farver, M., Smilowitz, J.T., The influence of early infant-feeding practices on the intestinal microbiome and body composition in infants. Nutr. Metab. Insights 8 (2015), 1–9.
190. Liu, A.H., Revisiting the hygiene hypothesis for allergy and asthma. J. Allergy Clin. Immunol. 136 (2015), 860–865.
191. Taylor, S.L., Wesselingh, S., Rogers, G.B., Host-microbiome interactions in acute and chronic respiratory infections. Cell. Microbiol. 18 (2016), 652–662.
192. Kelly, J.R., Kennedy, P.J., Cryan, J.F., Dinan, T.G., Clarke, G., Hyland, N.P., Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell. Neurosci., 9, 2015, 392.
193. Mullin, G.E., The gut Balance Revolution: Boost Your Metabolism, Restore Your Inner Ecology, and Lose the Weight for Good!. 2015, Rodale Books.
194. Sonnenburg, J., Sonnenburg, E., The Good gut: Taking Control of Your Weight, Your Mood, and Your Long-term Health. 2015, Penguin.
195. Gold, S.M., Voskuhl, R.R., Estrogen and testosterone therapies in multiple sclerosis. Prog. Brain Res., 2009, 239–251.
196. Su, K., Kimmy, S., Dennis, B., Michael, F., Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. Front. Physiol., 4, 2013, 10.3389/fphys.2013.00169.
197. Mao, P., Peizhong, M., Hemachandra, Reddy P., Is multiple sclerosis a mitochondrial disease?. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1802 (2010), 66–79.
198. Mahad, D.H., Trapp, B.D., Hans, L., Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14 (2015), 183–193.
199. Corthals, A.P., Multiple sclerosis is not a disease of the immune system. Q. Rev. Biol. 86 (2011), 287–321.
200. Mathur, D., López-Rodas, G., Casanova, B., Marti, M.B., Perturbed glucose metabolism: insights into multiple sclerosis pathogenesis. Front. Neurol., 5, 2014, 250.